Sandoz, a Swiss generic drugmaker, agrees to pay $265M to settle US pricing antitrust case, without admitting guilt.
Sandoz, a Swiss generic drugmaker, has agreed to pay $265 million to settle a pricing antitrust case in the United States. The case involved allegations of price-fixing and was brought in the US state of Pennsylvania. Under the agreement, Sandoz is resolving all damages claims without admitting to any wrongdoing in the case. The payment will be incorporated into Sandoz's 2023 results.
February 29, 2024
10 Articles